Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bolt Biotherapeutics Inc (NQ: BOLT ) 0.7383 +0.0033 (+0.45%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Bolt Biotherapeutics Inc < Previous 1 2 Next > Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, American Airlines, and Bolt and Encourages Investors to Contact the Firm August 02, 2024 From Bragar Eagel & Squire Via GlobeNewswire BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm July 31, 2024 From Schall Law Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm July 30, 2024 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm July 26, 2024 From Bragar Eagel & Squire Via GlobeNewswire SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt July 26, 2024 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bolt To Contact Him Directly To Discuss Their Options From Faruqi & Faruqi LLP Via GlobeNewswire BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm July 24, 2024 From Schall Law Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm July 22, 2024 From Bragar Eagel & Squire Via GlobeNewswire BOLT Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the Class Action Against Bolt Biotherapeutics, Inc. July 22, 2024 From Robbins LLP Via GlobeNewswire BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm July 22, 2024 From The Schall Law Firm Via Business Wire SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt July 18, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm July 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire BOLT Stockholders with Large Losses Should Contact Robbins LLP for Information About the Bolt Biotherapeutics, Inc. Class Action Lawsuit July 15, 2024 From Robbins LLP Via Business Wire ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT July 15, 2024 From The Rosen Law Firm PA Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SeaStar and Bolt and Encourages Investors to Contact the Firm July 13, 2024 From Bragar Eagel & Squire Via GlobeNewswire BOLT Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Class Action Against Bolt Biotherapeutics, Inc. July 10, 2024 From Robbins LLP Via GlobeNewswire BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! July 10, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire BOLT ALERT: Bragar Eagel & Squire, P.C. is Investigating Bolt Biotherapeutics, Inc. on Behalf of Bolt Stockholders and Encourages Investors to Contact the Firm July 09, 2024 From Bragar Eagel & Squire Via GlobeNewswire ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT July 08, 2024 From The Rosen Law Firm PA Via GlobeNewswire Bolt Biotherapeutics, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the BOLT Class Action July 08, 2024 From Robbins LLP Via Business Wire ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT July 05, 2024 From The Rosen Law Firm PA Via GlobeNewswire Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against Bolt Biotherapeutics, Inc. (BOLT) July 03, 2024 From Robbins LLP Via GlobeNewswire BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! July 03, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire ROSEN, A TOP RANKED LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT July 03, 2024 From The Rosen Law Firm, P.A. Via Business Wire Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team May 14, 2024 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update March 21, 2024 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference February 27, 2024 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Pacira Appoints Frank D. Lee as Chief Executive Officer December 21, 2023 From Pacira BioSciences Via GlobeNewswire Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu® December 05, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference November 07, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.